Search
Search
Ramin Tadayoni, MD, PhD; Arshad M. Khanani, MD; David S. Boyer, MD
Show Description +
In this panel discussion, three retina experts discuss the need for pre-invasive treatment options to manage patients with newly diagnosed diabetic macular edema (DME) many of whom currently go untreated. They explain the benefits and challenges of using invasive intravitreal injections, the current standard of care to treat DME, and highlight the potential of OCS-01 eye drops, currently in Phase 3 development, to shift the treatment paradigm to an earlier intervention and provide an additional treatment option for suboptimal responders to help control the disease.
Posted: 11/14/2023
Ramin Tadayoni, MD, PhD; Arshad M. Khanani, MD; David S. Boyer, MD
In this panel discussion, three retina experts discuss the need for pre-invasive treatment options to manage patients with newly diagnosed diabetic macular edema (DME) many of whom currently go untreated. They explain the benefits and challenges of using invasive intravitreal injections, the current standard of care to treat DME, and highlight the potential of OCS-01 eye drops, currently in Phase 3 development, to shift the treatment paradigm to an earlier intervention and provide an additional treatment option for suboptimal responders to help control the disease.
Posted: 11/14/2023
About Oculis
Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.
Learn more at oculis.com
Follow Oculis
.00_04_26_15.Still001%20(1)_1699991782.png?auto=compress,format&w=180)
.00_04_02_05.Still001%20(1)_1699991905.png?auto=compress,format&w=180)
.00_05_09_03.Still001%20(1)_1699992346.png?auto=compress,format&w=180)